Pharma collaboration in Russia: the dos and don’ts

Natalia Gulyaeva and Maria Sedykh of Hogan Lovells look at the main drivers of collaboration in the pharmaceutical sector and the legal issues to keep in mind when handling partnerships in Russia.

The life sciences industry has remained dynamic even in the years of economic downturn. Clearly, this high IQ industry is smart enough to adjust to the changing market conditions and to see the silver lining.

Russia has been called a “pharmerging” country along with China, India, Mexico, and other developing markets with large populations.  

These countries were once considered the saviours of big pharma companies, given the immense patent cliff in the US and Europe. But over the last few years, the sales growth in such “pharmerging” markets has decreased.